Ocular Therapeutix ($OCUL) Insider Trading & Smart Money Activity
Ocular Therapeutix, Inc. ($OCUL) has 4 insider trades, 2 13F position changes and 3 analyst ratings on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($234.42K), net -$234.42K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 3
- Net insider $ (12 mo)
- -$234.42K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 3
OCUL insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 2 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 3 · $234.42K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All OCUL insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Anderman ToddChief Legal Officer | Sell (Open-market sale) 10b5-1 | 11.98K sh | $87.36K | -1.7% | — | |||||
| Insider | Kaiser PeterChief Development Officer | Sell (Open-market sale) 10b5-1 | 9.99K sh | $70.43K | +8.3% | — | |||||
| Insider | Heier Jeffrey S.Chief Scientific Officer | Sell (Open-market sale) 10b5-1 | 10.87K sh | $76.63K | +8.3% | — | |||||
| Analyst | Chardan Capital | Reiterates to buy | PT $23 | -1.2% | -11.5% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $25 | +3.5% | -7.6% | Read | |||||
| Analyst | Baird | Reiterates to buy | PT $30 | +3.5% | -7.6% | Read | |||||
| Insider | Pravin DugelExecutive Chairman, President and CEO | Sell (Gift) | 50.09K sh | +13.2% | +2.5% | — | |||||
| 13F | Avoro Capital Advisors | Added | +1.54M sh | $125.18M | -10.2% | -1.9% | Read | ||||
| 13F | Avoro Capital Advisors | Added | +1.54M sh | $110.10M | -10.2% | -1.9% | Read |
1W / 1M / 6M = how OCUL moved from the trade or filing date.
Insider trading in OCUL: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Anderman Todd | Chief Legal Officer | 1 | -$87.36K | Oct 8, 2026 | |
| Kaiser Peter | Chief Development Officer | 1 | -$70.43K | Oct 2, 2026 | |
| Heier Jeffrey S. | Chief Scientific Officer | 1 | -$76.63K | Oct 2, 2026 | |
| Pravin Dugel | Executive Chairman, President and CEO | 1 | — | Jun 16, 2026 |
Institutions moving OCUL (13F)
Analyst ratings on OCUL
Frequently asked questions
Are OCUL insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 3 open-market sales worth $234.42K, a net -$234.42K.
What is the latest insider trade in OCUL?
Anderman Todd, Chief Legal Officer filed a sell (open-market sale) of 11.98K sh worth $87.36K on Oct 8, 2026.
Which institutions changed their OCUL positions?
Recent 13F filers moving the stock include Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.